Part 2 of MOXIe was a Phase 2 international, multicenter, double-blind, randomized, and placebo-controlled study in patients with Friedreich’s ataxia, a rare, progressive, and debilitating genetic disorder with no approved treatments.
Disclaimer
Omaveloxolone is an investigational drug. Safety and efficacy have not been established by any regulatory agency.